<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89197">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02111252</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-850/CPH-001</org_study_id>
    <secondary_id>U1111-1153-8702</secondary_id>
    <nct_id>NCT02111252</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects</brief_title>
  <official_title>An Open-label Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Intramuscular Injection of TAK-850 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a phase 1/2 study of a single intramuscular injection of TAK-850 in
      healthy Japanese adult participants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and immunogenicity of a single
      intramuscular injection of TAK-850  for 22 days in healthy Japanese adults
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency of solicited local and systemic adverse events</measure>
    <time_frame>For 22 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The frequencies of solicited local and systemic adverse events will be tabulated in its own, and by severity and day of onset.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>For 22 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The frequencies of all adverse reactions observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection rate of hemagglutination inhibition [HI] antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection rate is measured by HI antibody titer for each of the three strains, 21 days after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate of HI antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion rate is measured by HI antibody titer for each of the three strains, 21 days after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold increase in HI antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold increase in HI antibody titer for  each of the three strains, 21 days after vaccination, as compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>At Day 1, Day 8, Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs will include blood pressure, pulse rate, and respiratory rate. For continuous variables, summary statistics of measured values and respective changes from baseline will be calculated at each evaluation time point. In addition, figures illustrating individual changes will be created.
For discrete variables, shift tables (before and after vaccination) will be created.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory values</measure>
    <time_frame>At Day 1, Day 8, Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Laboratory values will include hematology, biochemistry and urianalysis tests. For continuous variables, summary statistics of measured values and respective changes from baseline will be calculated at each evaluation time point. In addition, figures illustrating individual changes will be created.
For discrete variables, shift tables (before and after vaccination) will be created.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in safety  electrocardiogram (ECG) parameters</measure>
    <time_frame>At Day 1 and Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The ECG data will be analyzed into 3 categories,  `normal`, `abonormal but not clinically significant` and `abonormal clinically significant`.
Using these variables, shift tables (before and after vaccination) will be created by individual participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of HI antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean titer (GMT) of HI antibody titer for each of the three strains, 21 days after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of single radial hemolysis (SRH) antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMT of single radial hemolysis (SRH) antibody titer for each of the three strains, 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate of  SRH antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection rate is measured by SRH antibody titer for each of the three strains, 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of  SRH antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion rate as measured by SRH antibody titer for each of the three strains, 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold increase in SRH antibody titer</measure>
    <time_frame>At Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold increase in SRH antibody titer for each of the three strains, 21 days after vaccination, as compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>TAK-850 0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.5 mL TAK-850 (15 Âµg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-850</intervention_name>
    <description>TAK-850 injection</description>
    <arm_group_label>TAK-850 0.5 mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. In the opinion of the investigator, the participant is capable of understanding
             and complying with protocol requirements.

             2. The participant signs and dates a written, informed consent form prior to the
             initiation of any study procedures.

             3. The participant is a healthy Japanese adult male or female. 4. The participant is
             aged 20 to 49 years, inclusive, at the time of informed consent.

             5. The participant has a body mass index (BMI) between 18.5 and 25.0 kg/m2,
             inclusive, at the time of eligibility evaluation.

             6. If the participant is a female of childbearing potential who is sexually active
             with a nonsterilized male partner agrees to use routinely adequate contraception from
             signing of informed consent throughout the duration of the study.

        Exclusion Criteria:

          -  1. The participant has received any investigational compound within 4 months prior to
             the initial injection of study vaccine.

             2. The participant has been vaccinated with seasonal influenza vaccine within 6
             months prior to the initial injection of study vaccine.

             3. The participant has a history of influenza infection within 6 months prior to the
             initial injection of study vaccine 4. The participant is a study site employee, an
             immediate family member of such an employee, or in a dependent relationship with a
             study site employee who is involved in the conduct of this study (e.g., spouse,
             parent, child, sibling), or may consent under duress.

             5. The participant has uncontrolled, clinically significant manifestations of
             neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal,
             urologic, endocrine or other disorders, which may impact the ability of the
             participant to participate or potentially confound the study results.

             6. The participant has an oral temperature â¥37.5Â°C prior to the initial injection of
             study vaccine on Day 1.

             7. The participant has any medically diagnosed or suspected immune deficient
             condition.

             8. The participant has an immune compromising condition or disease, or is currently
             undergoing a form of treatment or was undergoing a form of treatment that can be
             expected to influence immune response within 30 days prior to the initial injection
             of study vaccine. Such treatments include, but is not limited to, systemic or high
             dose inhaled corticosteroids (&gt;800 Î¼g/day of beclomethasone dipropionate or
             equivalent; the use of inhaled and nasal steroids that do not exceed this level will
             be permitted), radiation treatment or other immunosuppressive or cytotoxic drugs.

             9. The participant has received antipyretics within 4 hours prior to the initial
             injection of study vaccine.

             10. The participant has a history of Guillain- BarrÃ© Syndrome, demyelinating
             disorders (including acute disseminated encephalomyelitis [ADEM] and multiple
             sclerosis) or convulsions.

             11. The participant has a functional or surgical asplenia. 12. The participant has a
             rash, other dermatologic conditions or tattoos which may interfere with the
             evaluation of injection site reaction as determined by the Investigator.

             13. The participant has a history of, or is infected with the Hepatitis B Virus
             (HBsAgs), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).

             14. The participant has a known hypersensitivity to any component of TAK-850. 15. The
             participant has a history of severe allergic reactions or anaphylaxis. 16. The
             participant has a history of drug abuse (defined as any illicit drug use) or a
             history of alcohol abuse within 1 year prior to the initial injection of study
             vaccine or is unwilling to agree to abstain from alcohol and drugs throughout the
             study.

             17. The participant has received any blood products (e.g. blood transfusion or
             immunoglobulin) within 90 days prior to the initial injection of study vaccine.

             18. The participant has received a live vaccine within 4 weeks (28 days) or an
             inactivated vaccine within 2 weeks (14 days) prior to the initial injection of study
             vaccine.

             19. If female, the participant is pregnant or lactating or intending to become
             pregnant before signing informed consent, during, or within 1 month after
             participating in this study; or intending to donate ova during such time period.

             20. The participant has donated whole blood ?200 mL within 4 weeks (28 days), â¥400 mL
             within 12 weeks (84 days), â¥800 mL within 52 weeks (364 days), or blood components
             within 2 weeks (14 days) prior to the initial injection of study vaccine.

             21. The participant has abnormal (clinically significant) electrocardiogram (ECG) at
             the assessment prior to the initial injection of study vaccine.

             22. The participant has abnormal laboratory values that suggest a clinically
             significant underlying disease at the assessment prior to the initial injection of
             study vaccine, or the participant has the following lab abnormalities: alanine
             aminotransferase (ALT) and/or aspartate aminotransferase (AST) more than 3 times the
             upper limits of normal.

             23. In the opinion of the investigator or subinvestigator, the participant is
             unlikely to comply with protocol requirements or is considered ineligible for any
             other reason.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-800-778-2860 (USA &amp; EU)</phone>
    <email>medicalinformation@tpna.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
